After-Hours Action: Why Ginkgo Bioworks Stock Is Sliding

Shares of cell programming platform company Ginkgo Bioworks Holdings Inc DNA are moving lower after hours on the heels of a wider-than-expected quarterly loss

  • Q1 Revenue: $80.7 million beat estimates of $71.68 million
  • Q1 EPS: Loss of 11 cents missed estimates for loss of 9 cents

Ginkgo ended the quarter with approximately $1.2 billion in cash and equivalents, which is expected to provide the company with a "multi-year runway and a margin of safety in an otherwise challenging market environment."

Ginkgo said it added 13 new cell programs in the first quarter, up 18% year-over-year. 

"There is no doubt that we are going to be living in a challenging market environment for a while, but Ginkgo was built for these moments — we have worked hard to give ourselves a margin of safety so that we can relentlessly focus on our mission to make biology easier to engineer," said Jason Kelly, co-founder and CEO of Ginkgo.

FY23 Outlook: Ginkgo continues to expect to add 100 new cell programs to its platform this year. Full-year revenue is expected to be at least $275 million.

See Also: Why Unity Software Stock Is Rising After Hours

DNA Price Action: Ginkgo Bioworks shares were down 8.89% after the bell at $1.23 at the time of publication, per Benzinga Pro.

Photo: Arek Socha from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksAfter-Hours CenterMoversGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!